{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T05:24:54Z","timestamp":1739424294260,"version":"3.37.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,12]]},"DOI":"10.7759\/cureus.78905","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:27:41Z","timestamp":1739381261000},"source":"Crossref","is-referenced-by-count":0,"title":["Chemotherapy-Associated Cardiotoxicity: A Silent Threat Evidenced in a Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Felipe  A","family":"Mu\u00f1oz-Rossi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Santiago","family":"C\u00e1rdenas-Corredor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Fernando","family":"Saldarriaga Osuna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego A","family":"Guerra Kunze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Le\u00f3n-Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donovan A","family":"S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Mejia Nates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luis Felipe","family":"Franco Puente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pamela L","family":"Suarez Jaramillo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio  J","family":"Reche Martinez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Atlas of cancer mortality in Colombia. (2017). Accessed. October 5, 2022: https:\/\/www.ins.gov.co\/TyS\/programas-de-calidad\/Documentos%20Programa%20EEDDCARIO\/ATLAS_de_Mortalidad_por_cancer_en_C...."},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.25100\/cm.v49i1.3596","article-title":"Cancer incidence estimates and mortality for the top five cancer in Colombia, 2007-2011","volume":"49","author":"Pardo C","year":"2018","unstructured":"Pardo C, Cendales R. Cancer incidence estimates and mortality for the top five cancer in Colombia, 2007-2011. Colomb Med (Cali). 2018, 49:16-22. 10.25100\/cm.v49i1.3596","journal-title":"Colomb Med (Cali)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon AR","year":"2022","unstructured":"Lyon AR, L\u00f3pez-Fern\u00e1ndez T, Couch LS, et al.. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022, 43:4229-361. 10.1093\/eurheartj\/ehac244","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101591","article-title":"Chemotherapy induced cardiotoxicity: a state of the art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics","volume":"48","author":"Abdul-Rahman T","year":"2023","unstructured":"Abdul-Rahman T, Dunham A, Huang H, et al.. Chemotherapy induced cardiotoxicity: a state of the art review on general mechanisms, prevention, treatment and recent advances in novel therapeutics. Curr Probl Cardiol. 2023, 48:101591. 10.1016\/j.cpcardiol.2023.101591","journal-title":"Curr Probl Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2020.09.001","article-title":"NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients","volume":"54","author":"Blancas I","year":"2020","unstructured":"Blancas I, Mart\u00edn-P\u00e9rez FJ, Garrido JM, Rodr\u00edguez-Serrano F. NT-proBNP as predictor factor of cardiotoxicity during trastuzumab treatment in breast cancer patients. Breast. 2020, 54:106-13. 10.1016\/j.breast.2020.09.001","journal-title":"Breast"},{"key":"ref6","article-title":"Early screening of cardiotoxicity of chemotherapy by echocardiography and myocardial biomarkers","volume":"98","author":"Bouhlel I","year":"2020","unstructured":"Bouhlel I, Chabchoub I, Hajri E, Ernez S, Gouider J. Early screening of cardiotoxicity of chemotherapy by echocardiography and myocardial biomarkers. Tunis Med. 2020, 98:1017-23.","journal-title":"Tunis Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/biom14020199","article-title":"Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond","volume":"14","author":"Attanasio U","year":"2024","unstructured":"Attanasio U, Di Sarro E, Tricarico L, et al.. Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond. Biomolecules. 2024, 14:199. 10.3390\/biom14020199","journal-title":"Biomolecules"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano G","year":"2020","unstructured":"Curigliano G, Lenihan D, Fradley M, et al.. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Ann Oncol. 2020, 31:171-90. 10.1016\/j.annonc.2019.10.023","journal-title":"Ann Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6616265","article-title":"Assessment and management of cardiotoxicity in hematologic malignancies","volume":"2021","author":"Bojan A","year":"2021","unstructured":"Bojan A, Torok-Vistai T, Parvu A. Assessment and management of cardiotoxicity in hematologic malignancies. Dis Markers. 2021, 2021:6616265. 10.1155\/2021\/6616265","journal-title":"Dis Markers"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.0010","article-title":"Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer","volume":"30","author":"Romond EH","year":"2012","unstructured":"Romond EH, Jeong JH, Rastogi P, et al.. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2012, 30:3792-9. 10.1200\/JCO.2011.40.0010","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz G","year":"2014","unstructured":"Ezaz G, Long JB, Gross CP, Chen J. Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Heart Assoc. 2014, 3:e000472. 10.1161\/JAHA.113.000472","journal-title":"J Am Heart Assoc"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3747\/co.24.3349","article-title":"Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population","volume":"24","author":"Rushton M","year":"2017","unstructured":"Rushton M, Johnson C, Dent S. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population. Curr Oncol. 2017, 24:176-80. 10.3747\/co.24.3349","journal-title":"Curr Oncol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-007-9803-5","article-title":"The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines","volume":"107","author":"Dranitsaris G","year":"2008","unstructured":"Dranitsaris G, Rayson D, Vincent M, Chang J, Gelmon K, Sandor D, Reardon G. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat. 2008, 107:443-50. 10.1007\/s10549-007-9803-5","journal-title":"Breast Cancer Res Treat"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz460","article-title":"Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study","volume":"40","author":"Abdel-Qadir H","year":"2019","unstructured":"Abdel-Qadir H, Thavendiranathan P, Austin PC, et al.. Development and validation of a multivariable prediction model for major adverse cardiovascular events after early stage breast cancer: a population-based cohort study. Eur Heart J. 2019, 40:3913-20. 10.1093\/eurheartj\/ehz460","journal-title":"Eur Heart J"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.10.008","article-title":"Symptomatic heart failure in acute leukemia patients treated with anthracyclines","volume":"1","author":"Kang Y","year":"2019","unstructured":"Kang Y, Assuncao BL, Denduluri S, et al.. Symptomatic heart failure in acute leukemia patients treated with anthracyclines. JACC CardioOncol. 2019, 1:208-17. 10.1016\/j.jaccao.2019.10.008","journal-title":"JACC CardioOncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12265-020-10042-3","article-title":"The role of biomarkers in cardio-oncology","volume":"13","author":"Ananthan K","year":"2020","unstructured":"Ananthan K, Lyon AR. The role of biomarkers in cardio-oncology. J Cardiovasc Transl Res. 2020, 13:431-50. 10.1007\/s12265-020-10042-3","journal-title":"J Cardiovasc Transl Res"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.14797\/mdcj-15-4-258","article-title":"The role of cardiovascular imaging and serum biomarkers in identifying cardiotoxicity related to cancer therapeutics","volume":"15","author":"Agha A","year":"2019","unstructured":"Agha A, Zarifa A, Kim P, et al.. The role of cardiovascular imaging and serum biomarkers in identifying cardiotoxicity related to cancer therapeutics. Methodist Debakey Cardiovasc J. 2019, 15:258-66. 10.14797\/mdcj-15-4-258","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s00059-020-04957-5","article-title":"Echocardiography and biomarkers for the diagnosis of\u00a0cardiotoxicity","volume":"45","author":"Berliner D","year":"2020","unstructured":"Berliner D, Beutel G, Bauersachs J. Echocardiography and biomarkers for the diagnosis of\u00a0cardiotoxicity. Herz. 2020, 45:637-44. 10.1007\/s00059-020-04957-5","journal-title":"Herz"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00508-022-02031-0","article-title":"Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: position paper of the Heart Failure Working Group of the Austrian Society of Cardiology","volume":"134","author":"Bergler-Klein J","year":"2022","unstructured":"Bergler-Klein J, Rainer PP, Wallner M, et al.. Cardio-oncology in Austria: cardiotoxicity and surveillance of anti-cancer therapies: position paper of the Heart Failure Working Group of the Austrian Society of Cardiology. Wien Klin Wochenschr. 2022, 134:654-74. 10.1007\/s00508-022-02031-0","journal-title":"Wien Klin Wochenschr"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy","volume":"131","author":"Cardinale D","year":"2015","unstructured":"Cardinale D, Colombo A, Bacchiani G, et al.. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015, 131:1981-8. 10.1161\/CIRCULATIONAHA.114.013777","journal-title":"Circulation"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2013.08.026","article-title":"Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity","volume":"112","author":"Lotrionte M","year":"2013","unstructured":"Lotrionte M, Biondi-Zoccai G, Abbate A, et al.. Review and meta-analysis of incidence and clinical predictors of anthracycline cardiotoxicity. Am J Cardiol. 2013, 112:1980-4. 10.1016\/j.amjcard.2013.08.026","journal-title":"Am J Cardiol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.63138","article-title":"Detection of cardiotoxicity using right ventricular free wall longitudinal strain in low cardiovascular risk breast cancer patients receiving low-dose anthracycline treatment","volume":"16","author":"Gorgiladze N","year":"2024","unstructured":"Gorgiladze N, Shavdia M, Gaprindashvili T, Gogua E, Gachechiladze L, Gujabidze M, Pagava Z. Detection of cardiotoxicity using right ventricular free wall longitudinal strain in low cardiovascular risk breast cancer patients receiving low-dose anthracycline treatment. Cureus. 2024, 16:e63138. 10.7759\/cureus.63138","journal-title":"Cureus"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246764","article-title":"Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity","volume":"16","author":"Higgins AY","year":"2021","unstructured":"Higgins AY, Arbune A, Soufer A, et al.. Left ventricular myocardial strain and tissue characterization by cardiac magnetic resonance imaging in immune checkpoint inhibitor associated cardiotoxicity. PLoS One. 2021, 16:e0246764. 10.1371\/journal.pone.0246764","journal-title":"PLoS One"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2019.11.002","article-title":"Cardio-oncological management of patients","volume":"46","author":"Cardinale DM","year":"2019","unstructured":"Cardinale DM, Barac A, Torbicki A, Khandheria BK, Lenihan D, Minotti G. Cardio-oncological management of patients. Semin Oncol. 2019, 46:408-13. 10.1053\/j.seminoncol.2019.11.002","journal-title":"Semin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/332044-chemotherapy-associated-cardiotoxicity-a-silent-threat-evidenced-in-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T17:27:44Z","timestamp":1739381264000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/332044-chemotherapy-associated-cardiotoxicity-a-silent-threat-evidenced-in-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.78905","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2,12]]}}}